This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hjermstad, M. J. Articles by Kaasa, S. Search for Related Content PubMed PubMed Citation Articles by Hjermstad, M. J. Articles by Kaasa, S. Social Bookmarking                            What's this?

Health-Related Quality of Life 1 Year After Allogeneic or Autologous Stem-Cell Transplantation: A Prospective Study

From the Norwegian Cancer Society, Department of Oncology, Norwegian Radium Hospital, and Medical Department A, National Hospital, Oslo, Norway; Palliative Medicine Unit, Department of Oncology, Trondheim University Hospital, and Norwegian University of Science and Technology, Faculty of Medicine, Unit for Applied Clinical Research, Trondheim, Norway; and Medical Research Council Cancer Trials Office, Cambridge, United Kingdom.

Address reprint requests to Marianne Jensen Hjermstad, RN, MPH, Department of Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway; email mlhjerm{at}online.no

PURPOSE: To evaluate health-related quality of life (HRQOL) in adults treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem-cell transplantation 1 year after transplantation, using data from concurrent lymphoma patients receiving combination chemotherapy (CT) as a reference.

MATERIALS AND METHODS: Forty-one leukemia patients (SCT group), 51 lymphoma patients (ASCT group), and 85 CT patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire at baseline and after 1 year.

RESULTS: The SCT group (median age, 36 years) had better functioning scores and less symptomatology at baseline compared with the ASCT (median age, 41 years) and CT (median age, 37 years) groups. Statistically significant differences of 10 or more points on the 0 to 100 scales were found for 10 of 15 scales and items (P .01) between the SCT and ASCT groups. Global quality of life (79 v 58, P < .0001), role function (83 v 65, P = .001), sleep disturbances (6 v 28, P < .0001), and fatigue (25 v 44, P = .0001) deviated most. The differences were 10 or more points for seven of 15 scales and items comparing the SCT and CT groups, with sleep disturbances (6 v 35, P < .0001) and pain (11 v 29, P < .01) deviating most. Differences across groups were smaller after 1 year; cognitive function was the only scale with a statistically significant difference (ASCT 80 v CT 89; P = .002).

Patterns of change in HRQOL scores were different between groups during follow-up. A great improvement was found in the ASCT group (P < .01 for emotional and role function, fatigue, appetite, and constipation), whereas no significant changes were observed for the SCT group.

CONCLUSION: Prospective studies with extended follow-up periods are necessary to separate a slow recovery process from more permanently reduced HRQOL after transplantation and to examine the late side effects from previous treatment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Pidala, C. Anasetti, and H. Jim Quality of life after allogeneic hematopoietic cell transplantation Blood, July 2, 2009; 114(1): 7 - 19. [Abstract] [Full Text] [PDF]

				K. A. Goodman, E. Riedel, V. Serrano, S. Gulati, C. H. Moskowitz, and J. Yahalom Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5240 - 5247. [Abstract] [Full Text] [PDF]

				K. K. Ness, S. Bhatia, K. S. Baker, L. Francisco, A. Carter, S. J. Forman, L. L. Robison, J. Rosenthal, and J. G. Gurney Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With Hematopoietic Stem Cell Transplantation: The Bone Marrow Transplant Survivor Study Arch Pediatr Adolesc Med, August 1, 2005; 159(8): 706 - 713. [Abstract] [Full Text] [PDF]

				L. M. Nail My Get Up and Go Got Up and Went: Fatigue in People With Cancer J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 72 - 75. [Abstract] [Full Text] [PDF]

				K. L. Syrjala, S. L. Langer, J. R. Abrams, B. Storer, J. E. Sanders, M. E. D. Flowers, and P. J. Martin Recovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or Lymphoma JAMA, May 19, 2004; 291(19): 2335 - 2343. [Abstract] [Full Text] [PDF]

				H. Knobel, J. H. Loge, E. Brenne, P. Fayers, M. J. Hjermstad, and S. Kaasa The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors Palliative Medicine, December 1, 2003; 17(8): 664 - 672. [Abstract] [PDF]

				Y. Brandberg, H. Michelson, B. Nilsson, C. Bolund, B. Erikstein, P. Hietanen, S. Kaasa, J. Nilsson, T. Wiklund, N. Wilking, et al. Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401 J. Clin. Oncol., October 1, 2003; 21(19): 3659 - 3664. [Abstract] [Full Text] [PDF]

				K. Hartl, W. Janni, R. Kastner, H. Sommer, B. Strobl, B. Rack, and M. Stauber Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients Ann. Onc., July 1, 2003; 14(7): 1064 - 1071. [Abstract] [Full Text] [PDF]

				H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]

				S. Kaasa and J. H. Loge Quality of life in palliative care: principles and practice Palliative Medicine, January 1, 2003; 17(1): 11 - 20. [Abstract] [PDF]

				M. Hensel, G. Egerer, A. Schneeweiss, H. Goldschmidt, and A. D. Ho Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation Ann. Onc., February 20, 2002; 13(2): 209 - 217. [Abstract] [Full Text] [PDF]

				S. J. Lee, D. Fairclough, S. K. Parsons, R. J. Soiffer, D. C. Fisher, R. L. Schlossman, J. H. Antin, and J. C. Weeks Recovery After Stem-Cell Transplantation for Hematologic Diseases J. Clin. Oncol., January 1, 2001; 19(1): 242 - 252. [Abstract] [Full Text] [PDF]

				N. Mounier, C. Haioun, B. F. Cole, C. Gisselbrecht, C. Sebban, P. Morel, G. Marit, R. Bouabdallah, C. Ravoet, G. Salles, et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission Blood, June 15, 2000; 95(12): 3687 - 3692. [Abstract] [Full Text] [PDF]